Compare BRLT & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRLT | KTTA |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 18.1M |
| IPO Year | 2021 | N/A |
| Metric | BRLT | KTTA |
|---|---|---|
| Price | $1.06 | $0.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $1.70 | ★ $3.00 |
| AVG Volume (30 Days) | 36.3K | ★ 332.4K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $437,483,000.00 | N/A |
| Revenue This Year | $6.72 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.63 | N/A |
| 52 Week Low | $1.00 | $0.28 |
| 52 Week High | $3.10 | $2.06 |
| Indicator | BRLT | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 37.55 |
| Support Level | N/A | $0.28 |
| Resistance Level | $1.25 | $0.52 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 13.51 | 28.21 |
Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.